Unlocking Hope: BioInvent’s Triple Combo Treatment Shows Promising Results for Non-Hodgkin’s Lymphoma Patients
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)
The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment. One complete response (CR) and one partial response (PR). The treatment has been well-tolerated with no safety or tolerability concerns. Study now expanding to additional clinical investigational sites and patient enrollment on track with further Phase 2a results expected by mid-2025.
BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces promising initial clinical response data from the two enrolled patients in the triple combination arm of the Phase 1/2a study of its anti-FcyRIIB antibody, BI-1206, combined with rituximab and AstraZeneca’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence® (acalabrutinib), in non-Hodgkin’s lymphoma (NHL). The preliminary data demonstrates that the combination treatment is well tolerated with the two enrolled patients already showing clinical responses.
Non-Hodgkin’s Lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is a part of the body’s immune system. It is a diverse group of blood cancers that includes all types of lymphoma except Hodgkin’s lymphoma. Patients with NHL often undergo various treatment regimens, including chemotherapy, immunotherapy, and targeted therapy.
The promising results from BioInvent’s triple combo treatment involving BI-1206, rituximab, and Calquence® represent a significant advancement in the field of cancer immunotherapy. BI-1206, as an anti-FcyRIIB antibody, works by modulating the immune system to target cancer cells more effectively. Rituximab is a monoclonal antibody that specifically targets the CD20 antigen on B cells, a type of immune cell implicated in NHL. Calquence®, on the other hand, is a BTK inhibitor that disrupts a key signaling pathway in B cells, contributing to their elimination.
How Will This Affect Me?
If you or a loved one is currently battling non-Hodgkin’s Lymphoma, the promising results of BioInvent’s triple combo treatment offer hope for more effective and tolerable treatment options in the near future. This innovative approach combining multiple therapies could potentially improve patient outcomes and quality of life.
How Will This Affect the World?
The development of novel and first-in-class immune-modulatory antibodies like BI-1206, along with targeted therapies such as Calquence®, has the potential to revolutionize cancer treatment on a global scale. As more patients benefit from these advanced treatment options, the overall survival rates and prognosis for cancers like non-Hodgkin’s Lymphoma could improve significantly, leading to a positive impact on public health worldwide.
Conclusion
The preliminary clinical response data from BioInvent’s triple combo treatment for non-Hodgkin’s Lymphoma patients represents a promising step forward in the field of cancer immunotherapy. With the expansion of the Phase 2a study and further results expected by mid-2025, there is renewed hope for patients and healthcare providers alike. The potential impact of this innovative treatment approach could be transformative, offering new possibilities for improved outcomes and quality of life for individuals battling cancer.
